Spac backtrack confirms that the gene therapy bubble has burst
The omens look good for the upcoming Pulsar readout, but can Eylea keep its wet AMD stranglehold?
The group will need longer-term data to justify its huge valuation.
The Swiss group has likely been paying attention to industry developments as BCMA and CD40 go out, while Covid-19 and Tim-3 move up.
Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.